GlassScriptPhysician profile
Jude Anglade
NPI 1841436755
$1,750.30
in general payments reported to CMS, 2019-2025
19 companies · $432 in 2025
The $432 reported for 2025 was more than what 77% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $382 · 2022: $545 · 2023: $247 · 2024: $145 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $823.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $292.47 | 2021-2022 | |
| Royal Biologics, INC. | $193.33 | 2022 | |
| Heron Therapeutics, INC. | $143.83 | 2021-2023 | Zynrelef |
| Luye Pharma (USA) LTD. | $130.00 | 2025 | Erzofri Extended-Release |
| Acumed LLC | $120.89 | 2023 | Acumed |
| Alkermes, INC. | $112.76 | 2025 | Lybalvi |
| Endo Pharmaceuticals INC. | $111.31 | 2021-2024 | Xiaflex |
| Abbvie INC. | $110.33 | 2022-2025 | |
| Redhill Biopharma INC. | $109.34 | 2021 | |
| Convatec INC. | $82.80 | 2022-2024 | |
| Vertex Pharmaceuticals Incorporated | $71.58 | 2024-2025 | |
| Globus Medical, INC. | $60.87 | 2021 | |
| Axogen | $49.19 | 2024-2025 | Axoguard Ha+ Nerve Protector, Axoguard Nerve Connector, Avance Nerve Graft |
| Avanos Medical | $37.67 | 2025 | Standard Rf Disposables |
| Endo USA, INC. | $28.76 | 2025 | Xiaflex |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linvatec Corporation | $28.31 | 2025 | Linvatec Arthroscopy |
| American Regent | $24.93 | 2024 | Injectafer |
| Horizon Therapeutics Plc | $22.05 | 2022 | |
| Stryker Corporation | $19.88 | 2024 | T2 Alpha, Gamma, Hoffmann |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jude Anglade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.